Search

Displaying results 3371 - 3380 of 7450 in total
  1. Drug

    Dihydroergocornine

    go.drugbank.com/drugs/DB11273
    Approved

    Dihydroergocornine is one of the dihydrogenated ergot compounds that present very large hypotensive effects. It is an artificial derivative of the crude extract of ergot and later purified, ergocornine. The formation of dihydroergocornin...

    Categories: Heterocyclic Compounds with 4 or More Rings
  2. Drug

    Iron protein succinylate

    go.drugbank.com/drugs/DB11209
    Approved

    Mixtures: KOMFER FOL 40 MG/185 MCG ORAL COZELTI, 10 FLK., KOMFER FOL 40 MG/185 MCG ORAL COZELTI, 20 FLK.
  3. Drug

    Tridecactide

    go.drugbank.com/drugs/DB15687
    Investigational

    [A203210] Tridecactide, along with [metenkefalin], are under investigation as an immunomodulatory therapy for moderate to severe COVID-19.[L13874,L13877]

    Categories: Experimental Unapproved Treatments for COVID-19
  4. Drug

    Paramethadione

    go.drugbank.com/drugs/DB00617
    Approved

    Paramethadione is an anticonvulsant in the oxazolidinedione class. It is associated with fetal trimethadione syndrome, which is also known as paramethadione syndrome.

  5. Drug

    Piperazine

    go.drugbank.com/drugs/DB00592
    ApprovedVet approvedWithdrawn

    First used as a solvent for uric acid, the use of piperazine as an anthelmintic agent was first introduced in 1953. … Piperazine compounds mediate their anthelmintic action by generally paralyzing parasites, allowing the host body to easily remove or expel the invading organism.

  6. Drug

    mRNA-1283

    go.drugbank.com/drugs/DB22668
    ApprovedInvestigational

    previously approved COVID-19 mRNA vaccines, including the original [Moderna COVID-19 Vaccine], mRNA-1283 encodes only the immunodominant regions (NTD and RBD) of the SARS-CoV-2 spike protein, allowing for … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from

  7. Drug

    Maxy-G34

    go.drugbank.com/drugs/DB05718
    Investigational

    It is being developed by Maxygen, Inc. for the treatment of chemotherapy-induced neutropenia.

    Categories: Compounds used in a research, industrial, or household setting
  8. Target

    Cytochrome P450 1A1

    go.drugbank.com/bio_entities/BE0003543
    EnzymeTargetHumans

    Catalyzes two successive oxidative transformation of all-trans retinol to all-trans retinal and then to the active form all-trans retinoic acid (PubMed:10681376). … Displays different regioselectivities for polyunsaturated fatty acids (PUFA) hydroxylation (PubMed:15041462, PubMed:18577768).

    Synonyms: Cytochrome P450 form 6
  9. Drug

    Magnesium Aluminum Silicate

    go.drugbank.com/drugs/DB11230
    ApprovedWithdrawn

    It is refined to a powder for use in cosmetic and pharmaceutical applications as an absorbent, anticaking agent, opacifying agent, viscosity-increasing agent, suspending agent, tablet and capsule disintegrant

  10. Drug

    Bremelanotide

    go.drugbank.com/drugs/DB11653
    Approved

    [A179683] Since then it was investigated for its place in treating sexual dysfunction in men and women but is now only indicated for women.